Anhydrous enol oxaloacetate is under clinical development by MetVital and currently in Phase II for Fatigue. According to GlobalData, Phase II drugs for Fatigue does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Anhydrous enol oxaloacetate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anhydrous enol oxaloacetate overview
Anhydrous enol-oxaloacetate (AEO) is under development for the treatment of myasthenia gravis, amyotrophic lateral sclerosis (ALS), breast cancer, Alzheimer's disease, glioblastoma multiforme and for fatigue after resolution of COVID-19 infection. It is administered through oral route as a pill or capsule. The drug candidate acts by targeting AMP-protein activated Kinase (AMPK).
It was under development for the treatment of Parkinson's disease and traumatic brain injury, hepatocellular carcinoma.
MetVital overview
MetVital is a biopharmaceutical company that develops small molecular modulators to improve cellular metabolism. The company’s pipeline products include drugs for the treatment of general wellness, premenstrual syndrome, breast cancer and chronic fatigue syndrome. It also develops drugs for alzheimer’s disease, brain cancer, post covid fatigue, amyotrophic lateral sclerosis fatigue, and parkinson’s disease. The company is collaborated with national institute of neurological disorder and stroke for developing drugs for the epilepsy treatment. MetVital is headquartered in San Diego, California, the US.
For a complete picture of Anhydrous enol oxaloacetate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
